Excerpt from the article:

"Bromodomain inhibitors

Bromodomain proteins play a critical role in transcriptional regulation acting via histone acetylation, chromatin remodelling, and recruitment of other transcriptional machinery. Bromodomains are epigenetic readers with the BET (bromo and extra terminal) family garnering the most attention in drug discovery efforts [64]. One of the early compounds, molibresib, has undergone study in Phase I/II clinical trials for NUT midline carcinoma and castration-resistant prostate cancer with some evidence of clinical activity [6, 65, 66]. Other BET inhibitors in clinical development include pelabresib (CPI-0610) being tested in a Phase 3 study of myelofibrosis [67,68,69] and apabetalone (RVX-208), which is in late-stage development for cardiovascular disease and chronic kidney disease with promising results to date in the non-oncology setting [70]"

Koo